Charge-based interactions through peptide position 4 drive diversity of antigen presentation by human leukocyte antigen class I molecules

Abstract Human leukocyte antigen class I (HLA-I) molecules bind and present peptides at the cell surface to facilitate the induction of appropriate CD8+ T cell-mediated immune responses to pathogen- and self-derived proteins. The HLA-I peptide-binding cleft contains dominant anchor sites in the B and F pockets that interact primarily with amino acids at peptide position 2 and the C-terminus, respectively. Nonpocket peptide–HLA interactions also contribute to peptide binding and stability, but these secondary interactions are thought to be unique to individual HLA allotypes or to specific peptide antigens. Here, we show that two positively charged residues located near the top of peptide-binding cleft facilitate interactions with negatively charged residues at position 4 of presented peptides, which occur at elevated frequencies across most HLA-I allotypes. Loss of these interactions was shown to impair HLA-I/peptide binding and complex stability, as demonstrated by both in vitro and in silico experiments. Furthermore, mutation of these Arginine-65 (R65) and/or Lysine-66 (K66) residues in HLA-A*02:01 and A*24:02 significantly reduced HLA-I cell surface expression while also reducing the diversity of the presented peptide repertoire by up to 5-fold. The impact of the R65 mutation demonstrates that nonpocket HLA-I/peptide interactions can constitute anchor motifs that exert an unexpectedly broad influence on HLA-I-mediated antigen presentation. These findings provide fundamental insights into peptide antigen binding that could broadly inform epitope discovery in the context of viral vaccine development and cancer immunotherapy.

[1]  N. Salomonis,et al.  DeepImmuno: Deep learning-empowered prediction and generation of immunogenic peptides for T cell immunity , 2020, bioRxiv.

[2]  S. Justesen,et al.  Identification and validation of 174 COVID-19 vaccine candidate epitopes reveals low performance of common epitope prediction tools , 2020, Scientific Reports.

[3]  Jayvee R. Abella,et al.  Markov state modeling reveals alternative unbinding pathways for peptide–MHC complexes , 2020, Proceedings of the National Academy of Sciences.

[4]  Jayvee R. Abella,et al.  Structural Modeling and Molecular Dynamics of the Immune Checkpoint Molecule HLA-G , 2020, Frontiers in Immunology.

[5]  Kyle R Jackson,et al.  Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers , 2020, Nature Communications.

[6]  Conrad C. Huang,et al.  UCSF ChimeraX: Structure visualization for researchers, educators, and developers , 2020, Protein science : a publication of the Protein Society.

[7]  J. Yewdell,et al.  A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion , 2020, Nature Reviews Immunology.

[8]  Alex Rubinsteyn,et al.  MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing. , 2020, Cell systems.

[9]  Morten Nielsen,et al.  NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data , 2020, Nucleic Acids Res..

[10]  V. Velculescu,et al.  High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets , 2019, Cancer Immunology Research.

[11]  N. Hacohen,et al.  A large peptidome dataset improves HLA class I epitope prediction across most of the human population , 2019, Nature Biotechnology.

[12]  Katherine Luzuriaga,et al.  CDR3α drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection , 2019, PLoS pathogens.

[13]  G. Gao,et al.  Salt bridge-forming residues positioned over viral peptides presented by MHC class I impacts T-cell recognition in a binding-dependent manner , 2019, Molecular Immunology.

[14]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[15]  Alex Rubinsteyn,et al.  MHCflurry: Open-Source Class I MHC Binding Affinity Prediction. , 2018, Cell systems.

[16]  Peter V Coveney,et al.  Uncertainty Quantification in Alchemical Free Energy Methods , 2018, Journal of chemical theory and computation.

[17]  Sri H. Ramarathinam,et al.  The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis , 2018, The Journal of Biological Chemistry.

[18]  Lydia E. Kavraki,et al.  Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy , 2017, Front. Immunol..

[19]  Z. Weng,et al.  Emerging Concepts in TCR Specificity: Rationalizing and (Maybe) Predicting Outcomes , 2017, The Journal of Immunology.

[20]  David Gfeller,et al.  Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity , 2017, bioRxiv.

[21]  Didier Devaurs,et al.  Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data , 2017, Front. Mol. Biosci..

[22]  Jennifer G. Abelin,et al.  Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.

[23]  M. Nielsen,et al.  Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01 , 2017, The Journal of Biological Chemistry.

[24]  Haruki Nakamura,et al.  Protein Data Bank (PDB): The Single Global Macromolecular Structure Archive. , 2017, Methods in molecular biology.

[25]  F. Pazos,et al.  A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens* , 2016, Molecular & Cellular Proteomics.

[26]  David Gfeller,et al.  Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide–HLA Interactions , 2016, The Journal of Immunology.

[27]  Zhiping Weng,et al.  How structural adaptability exists alongside HLA-A2 bias in the human αβ TCR repertoire , 2016, Proceedings of the National Academy of Sciences.

[28]  Thomas J Lane,et al.  MDTraj: a modern, open library for the analysis of molecular dynamics trajectories , 2014, bioRxiv.

[29]  J. E. Brewer,et al.  NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.

[30]  F. Noé,et al.  Protein conformational plasticity and complex ligand-binding kinetics explored by atomistic simulations and Markov models , 2015, Nature Communications.

[31]  Charlotte M. Deane,et al.  Rapid, Precise, and Reproducible Prediction of Peptide-MHC Binding Affinities from Molecular Dynamics That Correlate Well with Experiment. , 2015, Journal of chemical theory and computation.

[32]  C. Keşmir,et al.  Zooming into the binding groove of HLA molecules: which positions and which substitutions change peptide binding most? , 2015, Immunogenetics.

[33]  James Robinson,et al.  The IPD and IMGT/HLA database: allele variant databases , 2014, Nucleic Acids Res..

[34]  Morten Nielsen,et al.  Uncovering the Peptide-Binding Specificities of HLA-C: A General Strategy To Determine the Specificity of Any MHC Class I Molecule , 2014, The Journal of Immunology.

[35]  C. Bailey-Kellogg,et al.  The two-faced T cell epitope , 2013, Human vaccines & immunotherapeutics.

[36]  Peter M. Kasson,et al.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..

[37]  Alexander D. MacKerell,et al.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. , 2012, Journal of chemical theory and computation.

[38]  Morten Nielsen,et al.  Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion , 2012, Nucleic Acids Res..

[39]  J. McCluskey,et al.  The Energetic Basis Underpinning T-cell Receptor Recognition of a Super-bulged Peptide Bound to a Major Histocompatibility Complex Class I Molecule* , 2012, The Journal of Biological Chemistry.

[40]  Rainer A Böckmann,et al.  Dynamical characterization of two differentially disease associated MHC class I proteins in complex with viral and self-peptides. , 2012, Journal of molecular biology.

[41]  Marialva Sinigaglia,et al.  Structural in silico analysis of cross-genotype-reactivity among naturally occurring HCV NS3-1073-variants in the context of HLA-A*02:01 allele. , 2011, Molecular immunology.

[42]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[43]  Cedric E. Ginestet ggplot2: Elegant Graphics for Data Analysis , 2011 .

[44]  B. Baker,et al.  Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition. , 2010, Journal of medicinal chemistry.

[45]  Feng Gao,et al.  Novel Immunodominant Peptide Presentation Strategy: a Featured HLA-A*2402-Restricted Cytotoxic T-Lymphocyte Epitope Stabilized by Intrachain Hydrogen Bonds from Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein , 2010, Journal of Virology.

[46]  F. Bonilla,et al.  Adaptive immunity. , 2010, The Journal of allergy and clinical immunology.

[47]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[48]  Søren Buus,et al.  Functional recombinant MHC class II molecules and high-throughput peptide-binding assays , 2009, Immunome research.

[49]  P. van Endert,et al.  Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition , 2009, Proceedings of the National Academy of Sciences.

[50]  M. Nielsen,et al.  Peptide Binding to HLA Class I Molecules: Homogenous, High-Throughput Screening, and Affinity Assays , 2009, Journal of biomolecular screening.

[51]  J. Shabanowitz,et al.  Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for presentation of transformed self , 2008, Nature Immunology.

[52]  M. Manns,et al.  Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. , 2008, Vaccine.

[53]  Ettore Appella,et al.  Single MHC mutation eliminates enthalpy associated with T cell receptor binding. , 2007, Journal of molecular biology.

[54]  J. Evanseck,et al.  Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu. , 2007, Molecular immunology.

[55]  G. Gao,et al.  Crystal structure of HLA‐A*2402 complexed with a telomerase peptide , 2006, European journal of immunology.

[56]  Natalie A Borg,et al.  High Resolution Structures of Highly Bulged Viral Epitopes Bound to Major Histocompatibility Complex Class I , 2005, Journal of Biological Chemistry.

[57]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[58]  Nathan A. Baker,et al.  PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations , 2004, Nucleic Acids Res..

[59]  M. Bouvier,et al.  Structures of HLA-A*1101 complexed with immunodominant nonamer and decamer HIV-1 epitopes clearly reveal the presence of a middle, secondary anchor residue. , 2004, Journal of immunology.

[60]  J. Yewdell,et al.  Making sense of mass destruction: quantitating MHC class I antigen presentation , 2003, Nature Reviews Immunology.

[61]  B. Baker,et al.  MHC Allele-Specific Molecular Features Determine Peptide/HLA-A2 Conformations That Are Recognized by HLA-A2-Restricted T Cell Receptors1 , 2002, The Journal of Immunology.

[62]  Brian M. Baker,et al.  Identification of a Crucial Energetic Footprint on the α1 Helix of Human Histocompatibility Leukocyte Antigen (Hla)-A2 That Provides Functional Interactions for Recognition by Tax Peptide/Hla-A2–Specific T Cell Receptors , 2001, The Journal of experimental medicine.

[63]  S. Muta,et al.  Changes at the floor of the peptide-binding groove induce a strong preference for proline at position 3 of the bound peptide: molecular dynamics simulations of HLA-A*0217. , 2000, Biopolymers.

[64]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[65]  B. Čatipović,et al.  Peptide Binding to MHC Class I is Determined by Individual Pockets in the Binding Groove , 1997, Scandinavian journal of immunology.

[66]  M F del Guercio,et al.  Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. , 1995, Journal of immunology.

[67]  C. Schönbach,et al.  Fine tuning of peptide binding to HLA-B*3501 molecules by nonanchor residues. , 1995, Journal of immunology.

[68]  Paul Bowness,et al.  Identification of T cell receptor recognition residues for a viral peptide presented by HLA B27 , 1994, European journal of immunology.

[69]  K. Parker,et al.  Pocket mutations of HLA-B27 show that anchor residues act cumulatively to stabilize peptide binding. , 1994, Biochemistry.

[70]  A Sette,et al.  Definition of specific peptide motifs for four major HLA-A alleles. , 1994, Journal of immunology.

[71]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[72]  H. Rammensee,et al.  Peptide motifs of closely related HLA class I molecules encompass substantial differences , 1992, European journal of immunology.

[73]  J. Coligan,et al.  The peptide binding specificity of HLA class I molecules is largely allele-specific and non-overlapping. , 1992, Molecular immunology.

[74]  J. Sacchettini,et al.  Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[75]  A. McMichael,et al.  A critical role for conserved residues in the cleft of HLA-A2 in presentation of a nonapeptide to T cells. , 1992, Science.

[76]  T. Elliott,et al.  Structural requirements for the peptide‐induced conformational change of free major histocompatibility complex class I heavy chains , 1992, European journal of immunology.

[77]  J. Casanova,et al.  Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule. , 1992, Journal of immunology.

[78]  F. Carbone Conformational constraints involved in MHC class I restricted antigen presentation. , 1991, International reviews of immunology.

[79]  J. Berzofsky,et al.  Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein , 1989, The Journal of experimental medicine.

[80]  K. Meyer zum Büschenfelde,et al.  Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens , 1989, The Journal of experimental medicine.

[81]  H. Grey,et al.  Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[82]  W. Taylor,et al.  A sequence pattern common to T cell epitopes. , 1988, The EMBO journal.

[83]  E. Goulmy,et al.  Y-antigen killing by T cells of women is restricted by HLA , 1977, Nature.

[84]  R. Zinkernagel,et al.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system , 1974, Nature.